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PURPOSE

Impact of the interaction between FS and PG

RESULTS

• From the preliminary screening FS and PG were chosen as the
independent factors for the design while drug load was kept
constant 5% and PEO made up the remaining amount.

• Bacteria are the major contributors to ocular infections worldwide. Bacterial infections, like
keratitis and endophthalmitis, if left untreated, can lead to visual impairments and
blindness.

Stability of the optimized formulation
Based on the RSM plots an optimized formulation was selected
form the design and kept on stability
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• Ophthalmic preparations of fluoroquinolone antibiotics are used frequently for the treatment
of patients with ocular bacterial infections due to their broad spectrum of activity.
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• Most of these are administered as eye drops with poor bioavailability due to pre-corneal
losses leading to frequent dosing.
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• Ocular inserts are promising as they enhance retention and permeation of drugs at the
ocular site, in addition to providing a prolonged drug release platform.
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• Moxifloxacin (MOX) is a commonly prescribed fluoroquinolone antibiotic. It is frequently
used off-label for the treatment of bacterial keratitis (BK) and endophthalmitis.
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Figure 3:Contour plot illustrating the effect of FS and PG on release

• Hence, ophthalmic inserts, prepared using hot-melt extrusion (HME), were evaluated as a
potential alternative dosage form for the delivery of MOX.
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% Cumulative MFX release

The current study sought to develop and optimize sustained release MOX loaded ophthalmic
inserts using Central Composite Design (CCD)

METHODS
• Drug-Polymer compatibility studies: The DSC profiles of the pure MOX, polymers
(Polyethylene oxide (PEO) and Eudragit™ FS-100 (FS)) and the extruded formulation
were obtained using a DSC 25, TA. The samples were exposed to a temperature range of
25-200°C with a ramp of 10°C/min.
• Preparation of MOX inserts using HME: The polymers, plasticizer and drug were mixed
in a mortar and pestle which was then fed into the 6-mm counter-rotating mini extruder. All
the formulations were extruded at a temperature of 90°C and screw speed of 50 rpm.
• Study design: Two factors 3 level CCD were applied with 13 experimental runs. The
amounts of Eudragit™ FS-100 and propylene glycol (PG) were chosen as the
independent variables. Cumulative percent release at 2h an 6h were chosen as the
dependent variables.
• Characterization: (1) Drug Content: Three sections from each formulation, were
randomly cut and weighed using an electronic balance. Thereafter, they were dissolved in
a 1:1 ratio of methanol and DMSO, followed by sonication for 20 min to dissolve the drug.
This solution was then diluted appropriately and analyzed by the HPLC method, as
discussed earlier to determine the amount of MOX present. (2) Release study: 8 mg of
the films in 10 ml of phosphate buffered saline at 37±2°C wherein the % cumulative
release and time required for the release to plateau were determined
• Response surface methodology (RSM) computations and one-factor plots for formulation
optimization was performed using Design Expert® software (version 11) for selecting the
most suitable formulation.
• Stability study: Optimized film was then evaluated for stability at 4°C and 25°C/60%RH.
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Figure 5: Stability of the optimized formulation at 4 °C

Figure 1: CCD experimental design space with varying levels of
the two independent factors -FS and PG.
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Figure 4: % Cumulative release at 2h as a function of % FS for fixed
amount of PG
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• From figure 3 and 4 it can be seen that the amount of FS has a
linear effect on release i.e., as the amount of FS increases the
amount of MOX released decreases.

Figure 2: Release profiles of the axial and center points from the design.
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• On the other hand, PG has relatively milder impact on the
Day 0
Day 30
• From 13 experimental CCD runs, only the axial and center points
release and shows quadratic behavior i.e., as PG is increased,
are shown in Fig 2. to clearly elucidate the behavior of FS and PG
the % of MOX released decreases initially, but after a certain
Figure 6: Stability of the optimized formulation at 25 °C/60 % RH
on release.
threshold, a faster release was observed.
• As seen above FS is acting as a sustained release polymer.
• .From figure 5 and 6 there was no significant difference observed
• Thus, we can observe a sustained release of MOX upto 24 h from • There is a significant interaction between FS and PG as the
in the drug content of the optimized formulation at 4°C as well as
these inserts.
at 25°C/60%RH.
amount of PG is increased (Fig. 4).

CONCLUSIONS
•

MOX loaded inserts were prepared using the HME method and optimized using CCD.

•

Amount of Eudragit™FS-100 and PG together have a significant effect on the film performance.

•

Optimized MOX insert was found to be stable upto 30 days.

•

Optimized insert was found to exhibit controlled release upto 24 hours, indicating that MOX inserts could be a potential alternative in the management of BK.
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